Abstract
No public abstract is available from the verified source records.
Keshav Narayan Alagarsamy, Emilee Bueckert, Mehak Gupta, D. Allison Milosevic, Sanjiv Dhingra
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Leading progress in heart regeneration and repair
10.1016/j.ceb.2019.07.005 · 2019
Global trends in atherosclerotic cardiovascular disease
10.1016/j.clinthera.2023.09.020 · 2023
Review on emerging therapeutic strategies for managing cardiovascular disease
10.2174/011573403x299265240405080030 · 2024
Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine
10.1161/hcg.0000000000000043 · 2018
Human induced pluripotent stem cell as a disease modeling and drug development platform—a cardiac perspective
10.3390/cells10123483 · 2021
A concise review on induced pluripotent stem cell-derived cardiomyocytes for personalized regenerative medicine
10.1007/s12015-020-10061-2 · 2021
Concise review: harnessing iPSC-derived cells for ischemic heart disease treatment
10.2478/jtim-2020-0004 · 2020
Induced pluripotent stem cell-derived smooth muscle cells to study cardiovascular calcification
10.3389/fcvm.2022.925777 · 2022
Murine “model” monotheism
10.1161/circresaha.115.307523 · 2015
Induced pluripotent stem cells: at the heart of cardiovascular precision medicine
10.1038/nrcardio.2016.36 · 2016
Human iPSC modeling of heart disease for drug development
10.1016/j.chembiol.2021.02.016 · 2021
Advances in stem cell modeling of dystrophin-associated disease: implications for the wider world of dilated cardiomyopathy
10.3389/fphys.2020.00368 · 2020
Searching for an experimental rodent model of heart failure with preserved ejection fraction: re-visited
10.1016/j.biopha.2022.113251 · 2022
Human induced pluripotent stem cell-derived cardiomyocytes to study inflammation-induced aberrant calcium transient
10.7554/elife.95867 · 2024
Use of human induced pluripotent stem cell–derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing
10.1161/res.0000000000000291 · 2019
The impact of CRISPR/Cas9 technology on cardiac research: from disease modelling to therapeutic approaches
10.1155/2017/8960236 · 2017
Pre-clinical evaluation of the efficacy and safety of human induced pluripotent stem cell-derived cardiomyocyte patch
10.1186/s13287-024-03690-8 · 2024
Unlocking personalized biomedicine and drug discovery with human induced pluripotent stem cell–derived cardiomyocytes: fit for purpose or forever elusive?
10.1146/annurev-pharmtox-010919-023309 · 2020
Why 90% of clinical drug development fails and how to improve it?
10.1016/j.apsb.2022.02.002 · 2022
Can the pharmaceutical industry reduce attrition rates?
10.1038/nrd1470 · 2004
Reengineering an antiarrhythmic drug using patient hiPSC cardiomyocytes to improve therapeutic potential and reduce toxicity
10.1016/j.stem.2020.08.003 · 2020
Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells
10.1016/j.celrep.2014.09.055 · 2014
MAP4K4 inhibition promotes survival of human stem cell-derived cardiomyocytes and reduces infarct size in vivo
10.1016/j.stem.2019.01.013 · 2019
CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy
10.1093/eurheartj/ehy249 · 2018
How to improve R&D productivity: the pharmaceutical industry's grand challenge
10.1038/nrd3078 · 2010
Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company
10.1101/cshperspect.a014092 · 2014
An analysis of the attrition of drug candidates from four major pharmaceutical companies
10.1038/nrd4609 · 2015
Evolution of strategies to improve preclinical cardiac safety testing
10.1038/nrd.2015.34 · 2016
When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis
10.1371/journal.pone.0147215 · 2016
High throughput physiological screening of iPSC-derived cardiomyocytes for drug development
10.1016/j.bbamcr.2016.03.003 · 2016
High throughput measurement of Ca2+ dynamics for drug risk assessment in human stem cell-derived cardiomyocytes by kinetic image cytometry
10.1016/j.vascn.2012.08.167 · 2012
An automated platform for assessment of congenital and drug-induced arrhythmia with hiPSC-derived cardiomyocytes
10.3389/fphys.2017.00766 · 2017
MUSCLEMOTION
10.1161/circresaha.117.312067 · 2018
Recent technological advancements in traction force microscopy
10.1007/s12551-019-00589-0 · 2019
HiPSCs derived cardiac cells for drug and toxicity screening and disease modeling: what micro- electrode-array analyses can tell us
10.3390/cells8111331 · 2019
High-throughput screening to identify chemical Cardiotoxic potential
10.1021/acs.chemrestox.0c00382 · 2021
In-depth mechanistic analysis including high-throughput RNA sequencing in the prediction of functional and structural cardiotoxicants using hiPSC cardiomyocytes
10.1080/17425255.2023.2273378 · 2024
Mechanism of Block and identification of the verapamil binding domain to HERG potassium channels
10.1161/01.res.84.9.989 · 1999
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cells
10.1038/s41598-020-62344-w · 2020
Computational determination of hERG-related cardiotoxicity of drug candidates
10.1186/s12859-019-2814-5 · 2019
Efficient and reproducible generation of human iPSC-derived cardiomyocytes and cardiac organoids in stirred suspension systems
10.1038/s41467-024-50224-0 · doi-reference
Induced pluripotent stem cell-derived cardiomyocytes: from regulatory status to clinical translation
10.1089/ten.teb.2023.0080 · doi-reference
Microstripe pattern substrate consisting of alternating planar and nanoprotrusive regions improved hiPSC-derived cardiomyocytes' unidirectional alignment and functional properties
10.1088/1748-605x/ad525d · doi-reference
Architecture design and advanced manufacturing of heart-on-a-chip: scaffolds, stimulation and sensors
10.1038/s41378-024-00692-7 · doi-reference
Extracellular matrix–mediated maturation of human pluripotent stem cell–derived cardiac monolayer structure and electrophysiological function
10.1161/circep.113.003638 · doi-reference
The harder the climb the better the view: the impact of substrate stiffness on cardiomyocyte fate
10.1016/j.yjmcc.2022.02.001 · doi-reference
Engineered microenvironments for maturation of stem cell derived cardiac myocytes
10.7150/thno.19441 · doi-reference
Cardiac ultrastructure inspired matrix induces advanced metabolic and functional maturation of differentiated human cardiomyocytes
10.1016/j.celrep.2022.111146 · doi-reference
Human perinatal stem cell derived extracellular matrix enables rapid maturation of hiPSC-CM structural and functional phenotypes
10.1038/s41598-020-76052-y · doi-reference
Metabolically driven maturation of human induced pluripotent stem cell derived cardiac microphysiological systems
10.1038/s41551-022-00884-4 · doi-reference
Bioresorbable polymeric scaffold in cardiovascular applications
10.3390/ijms21103444 · doi-reference
Artificial scaffolds in cardiac tissue engineering
10.3390/life12081117 · doi-reference
Advancements in tissue engineering for cardiovascular health: a biomedical engineering perspective
10.3389/fbioe.2024.1385124 · doi-reference
Recent advances in designing electroconductive biomaterials for cardiac tissue engineering
10.1002/adhm.202200055 · doi-reference
Electroconductive biomaterials for cardiac tissue engineering
10.1016/j.actbio.2021.08.031 · doi-reference
Biomanufacturing of a chitosan/collagen scaffold to drive adhesion and alignment of human cardiomyocyte derived from stem cells
10.1016/j.procir.2015.09.004 · doi-reference
Recent advances in tissue-engineered cardiac scaffolds—the progress and gap in mimicking native myocardium mechanical behaviors
10.3390/jfb14050269 · doi-reference
Current research trends and challenges in tissue engineering for mending broken hearts
10.1016/j.lfs.2019.05.012 · doi-reference
A three-dimensional culture system for generating cardiac spheroids composed of cardiomyocytes, endothelial cells, smooth-muscle cells, and cardiac fibroblasts derived from human induced-pluripotent stem cells
10.3389/fbioe.2022.908848 · doi-reference
Advancing cardiovascular tissue engineering
10.12688/f1000research.8237.1 · doi-reference
Thyroid and glucocorticoid hormones promote functional T-tubule development in human-induced pluripotent stem cell derived cardiomyocytes
10.1161/circresaha.117.311920 · doi-reference
Glucocorticoids promote structural and functional maturation of foetal cardiomyocytes: a role for PGC-1α
10.1038/cdd.2014.181 · doi-reference
The glucocorticoid receptor in cardiovascular health and disease
10.3390/cells8101227 · doi-reference
Glucocorticoid signaling in the heart: a cardiomyocyte perspective
10.1016/j.jsbmb.2015.03.009 · doi-reference
Tri-iodo-L-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells
10.1016/j.yjmcc.2014.04.005 · doi-reference
Thyroid hormone SIGNALLING and consequences for cardiac development
10.1530/joe-18-0704 · doi-reference
Thyroid hormone action in postnatal heart development
10.1016/j.scr.2014.07.001 · doi-reference
Recent advances in regulating the proliferation or maturation of human-induced pluripotent stem cell-derived cardiomyocytes
10.1186/s13287-023-03470-w · doi-reference
Thyroid hormone plays an important role in cardiac function: from bench to bedside
10.3389/fphys.2021.606931 · doi-reference
AKAP1 regulates mitochondrial dynamics during the fatty-acid-promoted maturation of human-induced pluripotent stem cell-derived cardiomyocytes as indicated by proteomics sequencing
10.3390/ijms24098112 · doi-reference
Small molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes
10.1186/s13287-022-03209-z · doi-reference
Metabolic environment in vivo as a blueprint for differentiation and maturation of human stem cell-derived cardiomyocytes
10.1016/j.bbadis.2020.165881 · doi-reference
TFPa/HADHA is required for fatty acid beta-oxidation and cardiolipin re-modeling in human cardiomyocytes
10.1038/s41467-019-12482-1 · doi-reference
Advances in 3D bioprinted cardiac tissue using stem cell-derived cardiomyocytes
10.1093/stcltm/szae014 · doi-reference
Independent compartmentalization of functional, metabolic, and transcriptional maturation of hiPSC-derived cardiomyocytes
10.1016/j.celrep.2024.114160 · doi-reference
Effects of docosahexaenoic acid or arachidonic acid supplementation on the behavior of cardiomyocytes derived from human pluripotent stem cells
10.32604/biocell.2023.028186 · doi-reference
Metabolic maturation media improve physiological function of human iPSC-derived cardiomyocytes
10.1016/j.celrep.2020.107925 · doi-reference
Distinct carbon sources affect structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells
10.1038/s41598-017-08713-4 · doi-reference
Inhibition of fatty acid oxidation enables heart regeneration in adult mice
10.1038/s41586-023-06585-5 · doi-reference
Culture in glucose-depleted medium supplemented with fatty acid and 3,3′,5-Triiodo-l-Thyronine facilitates purification and maturation of human pluripotent stem cell-derived cardiomyocytes
10.3389/fendo.2017.00253 · doi-reference